

RECEIVED
CENTRAL FAX CENTER

JAN 05 2006

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Date

Signature

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: Jing Wu, et al.

Serial No.: 10/733,877

Application Date: December 12, 2003

US Nat'l Entry

Date (if applicable): not applicable

For:

CYCLOALKYL, LACTAM, LACTONE AND RELATED
COMPOUNDS, PHARMACEUTICAL COMPOSITION
COMPRISING SAME, AND METHODS FOR INHIBITING β -
AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY
USE OF SUCH COMPOUNDS

Group Art Unit: 1624

Kifle, Bruck

Conf No.: 8138

Docket No.: Previously: 02021.0066-02000
Now: X-11230N**AMENDMENT AND PETITION TO CORRECT**
INVENTORSHIP UNDER 37 C.F.R. 1.48(b)Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Amendment and Petition

This amendment and petition is to delete the names of the following persons originally named as inventors and who are not the inventors of the invention now being claimed: Eugene D. Thorsett, Michael A. Pleiss, Lee H. Latimer, Varghese John, Stephen Freedman, Thomas C. Britton, Jon K. Reel, Bruce A. Dressman, Cynthia L. Cwi, James J. Droste, Steven S. Henry, Stacey L. McDaniel, William L. Scott, Russell D. Stuckey, and Warren J. Porter.

2. Claims Now On File

The claims in this application are as follows: claims 119-137 filed on January 5, 2006.

01/06/2006 FFANAEIA 00000095 050840 10733877

01 FC:1253 1020.00 DA

PAGE 3/13 * RCVD AT 1/5/2006 2:45:27 PM [Eastern Standard Time] * SVR:USPTO-EFAX-6/25 * DNIS:2738300 * CSID:3172776534 * DURATION (mm:ss):03:00

01/06/2006 FFANAEIA 00000095 050840 10733877

02 FC:1051 130.00 DA

Serial No.: 10/733,877


3. Diligence

This amendment and petition is being filed concurrently with the deletion of all claims for which the inventors who are being deleted made a contribution. The amendment is made to comply with a restriction requirement made by the Examiner.

4. Fee Payment

Please charge \$130.00, the surcharge required by §1.17(h), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840 in the name of Eli Lilly and Company. I enclose an original and two copies of this paper.

Respectfully submitted,



Robert D. Titus
Attorney for Applicants
Registration No. 40,206
Phone: 317-277-3729

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

05 January 2006